Vivus says impotence drug data good

	Tweet

An experimental impotence drug being developed by Vivus Inc. showed promise in promoting sex in a mid-stage clinical trial, the company said on Thursday, pushing shares up 12 percent in premarket trading.

Vivus said a study of 284 patients took either a placebo or the compound, avanafil, for 12 weeks at varying doses. Among those taking the highest dose of the drug, 64 percent had erections long enough for intercourse, the company said.

The company did not give a comparison figure for those taking the placebo.

Mountain View, California-based Vivus said patients taking avanafil did not show any signs of visual disturbances.

U.S. regulators last month reported 40 cases of Blindness in men taking several impotence drugs including Pfizer Inc.’s Viagra.

Vivus said the most common side effect among patients taking avanafil was headache.

Shares were bid at $3.74 in premarket trading, after closing at $3.34 on the Nasdaq on Wednesday. 

RELATED STORIES:
High drug prices   Major Breakthrough May Lead to Better Drugs for Diabetes, Other Diseases   Viagra helps childhood lung condition   The first and only fusion inhibitor for the treatment of HIV   New antibiotic fights tuberculosis, study shows   Short antibiotic course effective in COPD flare-ups   U.S. group calls for safer asthma drug compounds   Newer flu drugs more effective than old   Xenical OTC   Efficacy of blood pressure drug questioned   Viagra unlikely to trigger heart attack   Ranbaxy says WHO puts 7 AIDS drugs back on list

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]